收藏切换
Risk factor analysis of piperacillin-tazobactam-associated thrombocytosis
收藏切换
Lina CHEN1, Hongling MA1, Wudan1, Guleng Siri1, *, Libo DAI2, *
World Clinical Drug | 2026, 47(6) : 667 - 672
Less
收藏切换
World Clinical Drug | 2026, 47(6): 667-672
• Article •
Risk factor analysis of piperacillin-tazobactam-associated thrombocytosis
Full
Lina CHEN1, Hongling MA1, Wudan1, Guleng Siri1, *, Libo DAI2, *
Affiliations
  • 1.Department of Pharmacy, Inner Mongolia Autonomous Region People's Hospital, Hohhot 010017, Inner Mongolia Autonomous Region, China
  • 2.Department of Pharmacy, Hunan University of Medicine General Hospital, Huaihua 418000, Hunan Province, China
Published: 2026-06-10 doi: 10.13683/j.wph.2026.06.012
Outline
收藏切换
Objective

To analyze the clinical characteristics and risk factors of piperacillin-tazobactam-associated thrombocytosis.

Methods

The data of patients hospitalized in Inner Mongolia Autonomous Region People's Hospital who treated with piperacillin tazobactam from January 1, 2024 to December 31, 2024 were collected and divided into the thrombocytosis group and the platelet-normal group. The differences in demographic data, liver and kidney functions, coagulation functions, platelet counts, indicators of infections, and medication use of piperacillin tazobactam were compared between the two groups. Multivariate logistic regression analysis was used to identify risk factors for piperacillin-tazobactam-associated thrombocytosis.

Results

A total of 247 patients were included, 41 in the thrombocytosis group and 206 in the platelet normal group. Multivariate logistic regression analysis revealed that C-reactive protein(P=0.024), treatment duration(P=0.012), and baseline platelet count(P<0.001) were independent risk factors for thrombocytosis.

Conclusion

C-reactive protein, duration of medication and baseline platelet count are independent risk factors for piperacillin-tazobactam-associated thrombocytosis.

piperacillin tazobactam  /  thrombocytosis  /  risk factor
陈丽娜, 马红玲, 乌丹, 斯日古楞, 戴立波. 哌拉西林他唑巴坦相关血小板增多危险因素分析. 世界临床药物, 2026 , 47 (6) : 667 -672 . DOI: 10.13683/j.wph.2026.06.012
Lina CHEN, Hongling MA, Wudan, Guleng Siri, Libo DAI. Risk factor analysis of piperacillin-tazobactam-associated thrombocytosis[J]. World Clinical Drug, 2026 , 47 (6) : 667 -672 . DOI: 10.13683/j.wph.2026.06.012
Year 2026 volume 47 Issue 6
54
10
Cite this Article
BibTeX
Article Info
doi: 10.13683/j.wph.2026.06.012
  • Receive Date:2025-10-16
  • Online Date:2026-11-05
  • Published:2026-06-10
Article Data
Affiliations
History
  • Received:2025-10-16
Funding
Affiliations
    1.Department of Pharmacy, Inner Mongolia Autonomous Region People's Hospital, Hohhot 010017, Inner Mongolia Autonomous Region, China
    2.Department of Pharmacy, Hunan University of Medicine General Hospital, Huaihua 418000, Hunan Province, China
References
Share
https://castjournals.cast.org.cn/joweb/sjlcyw/EN/10.13683/j.wph.2026.06.012
Share to
QR

Scan QR to access full text

Cite this article
BibTeX
Citations
表12种不同金属材料的力学参数
科
Family
属数
Number of
genus
种数
Number of
species
占总种数比例
Percentage of
total species (%)
属
Genus
种数
Number of
species
占总种数比例
Percentage of total
species (%)
鹅膏菌科Amanitaceae 2 11 5.26 鹅膏菌属 Amanita 10 4.78
小菇科 Mycenaceae 2 12 5.74 丝盖伞属 Inocybe 5 2.39
多孔菌科 Polyporaceae 8 14 6.70 蜡蘑属 Laccaria 5 2.39
红菇科 Russulaceae 3 23 11.00 小皮伞属 Marasmius 6 2.87
小菇属 Mycena 11 5.26
光柄菇属 Pluteus 5 2.39
红菇属 Russula 17 8.13
栓菌属 Trametes 5 2.39
关闭全屏
  • BibTeX
  • EndNote
  • RefWorks
  • TxT